Introduction
============

Chronic widespread pain (CWP), including fibromyalgia syndrome (FMS), is a complex pain condition characterized by generalized musculoskeletal pain and is often associated with symptoms such as tiredness, sleep disturbance, depression, anxiety, and cognitive difficulties ([@B70]; [@B2]; [@B57]). Chronic pain not only affects the patients but also affects their families and society, leading to extensive suffering and high economic costs ([@B10]).

Diagnosis of CWP is based on clinical examinations and criteria included in the American College of Rheumatology (ACR 90) definition of FMS ([@B70]). Hence, CWP means that pain has to be chronic (\>3 months duration) and widespread (i.e., in the spine and in at least three out of four defined body quadrants or in the spine and in contralateral quadrants). Diagnosis of FMS also requires generalized hyperalgesia (examined using tender point examination). In the European adult population, the prevalence of CWP is about 10%, with a higher prevalence for females ([@B6]; [@B10]; [@B14]; [@B47]). Furthermore, the variety of symptoms among CWP and the complex multifactorial etiology make it difficult to study the biological mechanisms behind CWP, mechanisms that need further elucidation. Although both central and peripheral mechanisms may contribute to the perceived pain in CWP, ([@B64], [@B63]; [@B23]) no valid biological markers have been identified for the activated nociceptive mechanisms in chronic pain conditions, including CWP. This and other studies from our group focus on exploring such activated mechanisms with the long-term goal of identifying clinically applicable biomarkers that can facilitate mechanism-based diagnoses and choice of treatments. Many biomarker studies have analyzed protein patterns, cytokines/chemokines, lipids, and metabolites in plasma/serum, muscles, and saliva to understand activated nociceptive mechanisms in patients with CWP/FMS ([@B5]; [@B73]; [@B32]; [@B15]; [@B24]; [@B55]; [@B66]). Taken together, these studies clearly indicate that peripheral (muscle and/or blood) nociceptive and inflammatory mechanisms are active and differ between patients and healthy controls.

One important aspect of pain both clinically and in research is pain intensity, which is registered using self-reported pain scales such as numeric rating scale (NRS) or visual analog scale (VAS) ([@B20]; [@B21]; [@B37]). Recently, we reported that pain intensity correlated significantly with the muscle protein pattern in CWP ([@B56]) and that several of the identified significant proteins were involved in stress and inflammatory responses and metabolic pathways. However, it is not known whether such a relationship exists between pain intensity and the protein pattern in blood. As mentioned above, psychological distress is common in CWP and is often measured using the Hospital Anxiety and Depression Scale (HADS) ([@B75]). Because the association between depression and several serum proteins has been shown in patients with major depression disorder, ([@B41]; [@B59]) it is important to investigate whether the protein pattern in blood correlates with psychological distress in CWP patients and to what extent these proteins influence pain intensity. The same principal reasoning goes for Body Mass Index (BMI) since increased BMI is often found in patients with CWP/FMS ([@B52]) and the correlation between limited numbers of plasma/serum metabolites and proteins and BMI have been reported ([@B72]; [@B60]).

Using proteomics to investigate disease specific markers in plasma and serum is common in the cardiovascular, cancer, and neurodegenerative research ([@B27]). There are at least two advantages with analyzing plasma: its rich protein content is easily accessed and since blood is in direct contact with all tissues, changes in peripheral tissues can be easily detected ([@B1]). However, plasma proteomic studies comprise several challenges. Plasma contains a complex mixture of proteins with large dynamic range, dominated by high abundant proteins such as albumin and immunoglobulins ([@B1]). Multidimensional fractionation or depletion techniques are required to sufficiently reduce sample complexity ([@B11]). Mass spectrometry in combination with various separation methods such as two-dimensional gel electrophoresis (2-DE) and liquid chromatography (LC) can identify thousands of proteins in a single analysis, and this information can be used to study how proteins are expressed and regulated ([@B30]; [@B68]). This strategy has successfully been applied in multiple quantitative proteomic studies of the cerebral spinal fluid (CSF) and serum of subjects with chronic low back pain (with and without pain related to lumbar disk hernia) ([@B44]; [@B74]). Compared to other separation methods, 2-DE provides a high quality of protein resolution as shown by its capability to resolve many post-translationally modified proteins that appear as isoforms.

Previously, we used 2-DE to investigate the plasma proteome between CWP patients and healthy controls ([@B66]). We found several proteins belonging to inflammatory, immunity, and metabolic processes that could discriminate the CWP and CON group. Based on these results, we now want to investigate the correlation between the altered proteins and pain intensity, depression, and anxiety. To the best of our knowledge, this type of investigation has not been reported. The analysis of the plasma proteome and investigation of associated symptoms in CWP patients using proteomics could improve the knowledge of the activated biological mechanisms in CWP.

Here, we investigated the correlation between pain intensity, psychological distress, and plasma proteins among CWP patients and controls and analyzed the possible influences of BMI and age on such relationships.

Materials and Methods {#s1}
=====================

Subjects
--------

The recruitment process, including inclusion and exclusion criteria, for CWP patients and healthy controls (CON) has previously been described in detail ([@B25]). None of the included subjects used any type of opioid, steroidal, or anticoagulatory medication. Exclusion criteria also included medical history record of bursitis, tendonitis, capsulitis, post-operative conditions in the neck/shoulder area, previous neck trauma, disorder of the spine, neurological disease, rheumatoid arthritis or any other systemic diseases, metabolic disease, malignancy, severe psychiatric illness or pregnancy, or difficulties understanding the Swedish language.

The healthy CON group consisted of women between 20 and 65 years. They were recruited through local newspaper advertisements. Women with CWP were recruited from former patients with CWP at the Pain and Rehabilitation Centre of the University Hospital, Linköping, Sweden and from an organization for FMS patients. As reported in previous studies, ([@B26], [@B25]; [@B29]) a total of 19 CWP and 24 CON were initially recruited in the original study. However, four participants were not used because there were difficulties collecting blood samples (two CWP subjects) and because two plasma samples (one CWP and one CON) were insufficient for further proteomic analysis. This resulted in 16 CWP and 23 CON samples. Hence, the proteomic data that this present study is based on has previously been published ([@B66]). However, in this present study, one of the CWP patients was excluded due to unclear diagnosis after detailed analysis and due to the fact that this patient had incomplete data in the health questionnaire. This exclusion resulted in statistical analysis of 38 plasma samples in this present study, 15 plasma samples from CWP and 23 from CON.

To confirm the individual eligibility, all participants (CWP and CON) received a standardized clinical examination. The ACR 90 criteria were used for classification of FMS/CWP ([@B70]). The recruiting process started in January 2010 and finished in May 2011. Hence, the revised ACR criteria from 2016 was not available. The examination was followed by a health questionnaire (see below). At the clinical examination, weight and height were registered. Based on these measurements, BMI (kg/m^2^) was calculated as weight (kg)/height (m)^2^ and classified according to the criteria developed by the World Health Organization (WHO): \< 18.5 = underweight; 18.5--24.9 = normal range; 25.0--29.9 = overweight; and ≥30.0 = obesity.

All participants signed a written consent form before the start of the study after receiving verbal and written information about the objectives and procedures of the study. The study was approved by the Regional Ethical Review Board in Linköping, Sweden (Dnr: M10--08, M233--09, Dnr: 2010/164--32) and followed the guidelines according to the Declaration of Helsinki. All methods were carried out in accordance with the approved ethical application.

Methods
=======

All subjects answered a health questionnaire consisting of the following items and scales.

Demographic Data
----------------

Each subject reported age (years).

Pain Intensity and Duration
---------------------------

Each subject rated the pain intensity in the neck-shoulder region, low back and whole body using an 11 grade (0 -- 10) NRS with two endpoints: zero indicating no pain at all and 10 indicating worst possible pain ([@B21]). CWP patients also reported the pain duration (years).

Hospital Anxiety and Depression Scale (HADS)
--------------------------------------------

The HADS is a short self-assessment questionnaire that measures anxiety and depression ([@B75]). HADS comprises seven items in each of the depression and anxiety scales (HAD-Depression and HAD-Anxiety). The subscale scores range between 0 and 21, with the lower score indicating the least depression and anxiety possible ([@B75]). HADS is frequently used both in clinical practice and in research and has good psychometric characteristics ([@B75]; [@B8]). It is also validated in its Swedish translation ([@B43]). In this study, a total score of HADS (denoted HADS-total), which includes both the anxiety and depression scores, was used to indicate psychological distress.

Other Background Variables
--------------------------

To get a comprehensive description of the subjects also data from the Pain Catastrophizing Scale (PCS) and Quality of Life instrument (QoL) are reported; for details about these instruments see our previous studies ([@B25]; [@B66]).

Sample Collection
-----------------

Before blood sampling, all participants were asked not to take any non-steroidal anti-inflammatory drugs for 7 days and/or paracetamol medication 12 h before the sampling. Venous blood samples were collected in EDTA vacutainer and centrifuged at 1000 × *g* for 15 min. The plasma was collected, aliquoted, and stored at −70°C. All samples were blinded before analysis.

Two-Dimensional Gel Electrophoresis (2-DE)
------------------------------------------

The procedure for 2-DE, including sample preparation, has previously been described in detail ([@B30]; [@B54]; [@B66]). In brief, depleted plasma samples containing 100 μg total protein were run in the first dimension, followed by second dimension separation using Ettan^TM^ DALTsix Electrophoresis Unit (Amersham, Pharmacia, Uppsala, Sweden). The protein gels were fluorescently stained using SYPRO Ruby^®^ (Bio-Rad Laboratories, Hercules, CA, United States). The stained protein pattern was visualized using a charge coupled device camera (VersaDoc^TM^ Imaging system 4000 MP, Bio-Rad) and further analyzed and quantified using PDQuest Advanced (v. 8.0.1, Bio-Rad). The amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels in the spot, and expressed as integrated optical density (IOD). Quantified protein data were then analyzed with multivariate statistics. The coefficient of variation of 2-DE was less than 25%, which is in line with what others have found with 2-DE ([@B45]). Two preparative gels (one pool from CWP and one from CON, containing 400 μg of total protein) for protein identifications were run according to the above protocol.

Protein Identification
----------------------

For identification, protein spots of interest were excised from the preparative gels, de-stained, subjected to tryptic digestion, and prepared as previously described ([@B54]). Briefly, the gel piece was incubated in 50% acetonitrile (ACN) in 25 mM ammonium bicarbonate, dehydrated in 100% ACN, dried in SpeedVac, and trypsinated in 37°C over night. The supernatant was transferred to a new tube, and the peptides were further extracted from the gel piece by incubation of 5% trifluoroacetic acid (TFA) in 50% ACN for 4 h. The pooled supernatants were dried and stored at −20°C until analysis.

Briefly, for MALDI-TOF analysis, peptides were reconstituted in 4 μl 0.1% TFA. The peptides were mixed in a 1:1 ratio with matrix solution (dihydroxybenzoic acid in 70% acetonitrile/0.3% TFA) and 1 μl was spotted on a target plate (stainless steel). The peptide masses were analyzed and the mass range of 300--3500 Da was used, including external mass calibration using a peptide calibration standard (Bruker) ([@B55]).

Low abundant proteins were identified with a nano liquid chromatography system (EASY-nLC, Thermo Scientific, Waltham, MA, United States) coupled to an LTQ Orbitrap Velos Pro MS (Thermo Scientific). The same procedure for LC-MS analysis was used as described earlier with minor adjustments in time ([@B55]). Peptides were dissolved in 6 μl 0.1% formic acid (FA) and loaded on a C18 column (100 mm × 75 μM, particle size 5 μM). The flow rate was set to 300 nL/min and the gradient buffer contained 0.1% FA in water (buffer A) and 0.1% FA in ACN (buffer B). Buffer B was used in a linear gradient (0--100%) for 30 min to separate the peptides.

Database Search and Bioinformatics
----------------------------------

The acquired MS data from MALDI-TOF analysis was pre-processed using flexAnalysis v. 3.4 (Bruker Daltonik), and the major peak list from each processed spectra was imported in the search engine ProteinProspector MS-Fit (v. 5.14.4), including the Swiss-Prot database v. 2015.3.5, as described in previous studies ([@B55]; [@B66]). Parameter restriction was made based on species (*Homo sapiens*), mass tolerance (50 ppm), maximum miss cleavages by trypsin (≤1), fixed modifications (carbamidomethylation of cysteine), and possible dynamic modifications (oxidation of methionine).

The acquired MS data from the Orbitrap were analyzed with MaxQuant v. 1.5.8.3 (Max Planck Institute of Biochemistry, Martinsried, Germany) using the human UniProt/Swiss-Prot database (downloaded 20170404) as described previously ([@B55]). The analysis parameters were as follow: mass tolerance (0.5 Da), parent ion tolerance (6 ppm), miss cleavages by trypsin (maximum 2), fixed modifications (carbamidomethylation of cysteine), and variable modification (oxidation on methionine and N-terminal acetylation). A false discovery rate of \<1% was used and at least two unique peptides were needed to be considered as identified. The identified proteins were divided in different groups based on UniProt database ^[1](#fn01){ref-type="fn"}^ definition on biological process.

Statistics
----------

### Univariate Statistics

For comparison of group differences regarding clinical background data, pain intensity, and HADS, Student's *t*-test and the non-parametric Mann--Whitney *U*-test were applied (IBM SPSS v. 24.0, IBM, United States) for normal distributed data and for non-normally distributed data, respectively, *p* \< 0.05 was considered significant.

### Multivariate Data Analysis (MVDA)

To investigate the multivariate correlations between the proteins (*X*-variables) and the clinical variables (*Y*-variables), OPLS was applied using SIMCA-P+ v. 13.0 (UMETRICS, Umeå, Sweden) ([@B19]). When applying MVDA, we followed the recommendations concerning omics data presented by Wheelock and Wheelock ([@B69]). The procedure of MVDA has been described in detail elsewhere ([@B54], [@B55]; [@B66]).

Briefly, PCA was used before all OPLS analysis in order to check for multivariate outliers. Furthermore, OPLS was used for the regression analyses of pain intensity, depressive and anxiety symptoms (HADS-total), BMI, and age using the detected proteins as regressors (*X*-variables) and clinical variables as *Y*-variables. All variables were mean centered, scaled for unified variance (UV-scaling), and transformed (log) if necessary ([@B19]). Variable influence on projection (VIP) value \>1.0 combined with jack-knifed 95% confidence intervals in the regression coefficients plot not including zero were considered significant. In the present study, the analysis was made in two steps. First, all proteins were included and from this analysis selected proteins with VIP \> 1.0 were used in a new regression presented in the results. Second, the significant (VIP \> 1.0) proteins were identified. In the tables, p(corr) is presented for each significant variable. This is the loading of each variable scaled as a correlation coefficient and thus standardizing the range from −1 to +1 ([@B69]). Furthermore, for each OPLS model, R^2^ and Q^2^ are displayed describing the goodness of fit and goodness of prediction of each model ([@B19]). To validate the model, we used cross validated analysis of variance (CV-ANOVA), and *p* ≤ 0.05 was considered a significant model. All presented variables are in accordance with Wheelock and Wheelock ([@B69]).

Results
=======

Clinical Background Data
------------------------

No significant differences were found between CWP and CON regarding height, weight, and BMI. The CWP group was significantly older and reported significantly higher HADS-total compared to CON. As expected, the pain intensity, as measured by NRS, was significantly higher in the CWP group. CWP also reported lower quality of life as well as more catastrophizing thoughts (Table [1](#T1){ref-type="table"}).

###### 

Demographic data, clinical measurements of pain intensity (NRS) and other pain characteristics, presented as mean values (±1 standard deviation) and median (min--max).

  Variables                      CON (*n* = 23)   CWP (*n* = 15)     *p*-value                       
  ------------------------------ ---------------- ------------------ ------------- ----------------- -------------
  Age (years)                    41.0 ± 10.2      42.0(27--56)       49.2 ± 8.9    50.0(31--62)      0.015^a^
  Height (cm)                    168.7 ± 7.3      169(153--181)      167.1 ± 5.0   169(156--173)     0.473^b^
  Weight (kg)                    68.7 ± 11.2      69.0(50--100)      72.8 ± 15.9   68.0(53--105)     0.351^b^
  BMI (kg/m^2^)                  24.0 ± 2.8       23.2(19.5--31.9)   26.0 ± 5.0    23.8 (20--35.6)   0.133^b^
  Pain duration (years)          NA               NA                 12.9 ± 8.4    10.0(4.0--34)     NA
  NRS (whole body)               0.0 ± 0.0        0.0(0.0--0.0)      4.9 ± 2.0     5.0(1.0--8.0)     \< 0.001^b^
  Pain the last 7 days                                                                               
  Neck (NRS)                     0.1 ± 0.4        0.0(0.0--2.0)      5.7 ± 2.4     6.0(0.0--9.0)     \< 0.001^b^
  Shoulders (NRS)                0.0 ± 0.0        0.0(0.0--0.0)      5.7 ± 1.9     6.0(2.0--8.0)     \< 0.001^b^
  Low back (NRS)                 0.0 ± 0.0        0.0(0.0--0.0)      5.9 ± 1.6     6.0(3.0--9.0)     \< 0.001^b^
  HADS depression                1.3 ± 1.6        1.0(0.0--6.0)      6.1 ± 3.4     6.0(1.0--13)      \< 0.001^a^
  HADS anxiety                   1.9 ± 1.9        1.0(0.0--7.0)      7.9 ± 3.2     6.0(5.0--14)      \< 0.001^a^
  HADS total                     3.3 --2.8        2.0(0.0--9.0)      14.0 ± 5.3    13.0(7.0--24)     \< 0.001^a^
  PCS                            6.7 ± 6.4        5.0(0.0--19.0)     13.0 ± 7.5    13.0(4.0--29)     0.011^a^
  QoL                            93.1 ± 9.7       94(74--111)        82.5 ± 13.1   85.0(57--103)     0.007^b^
  Also diagnosed with FM (*n*)   NA               NA                 13            NA                NA

Statistical test used:

a

Mann--Whitney U-test,

b

Student t-test. NRS, numeric rating scale; BMI, body mass index; HADS, hospital Anxiety and depression scale; SD, standard deviation; CON, control; CWP, chronic widespread pain; NA, Not applicable; PCS, pain catastrophizing scale; QoL, Quality of life; FM, fibromyalgia. Please note that these data (not the exact same number of patients) have been published earlier (

Wåhlén et al., 2017

).

2-DE Analysis
-------------

A total of 414 ± 21 (CWP: 425 ± 18, CON: 408 ± 20) plasma proteins, including different isoforms (in the following termed proteoforms) from each gel, were detected in the 2-DE analysis, and 325 proteins were further quantified, matched, and analyzed with OPLS models. The quantified proteins were initially analyzed with an unsupervised PCA to detect outliers. In this study, no moderate or strong outliers were found. Most of the significantly protein spots were identified in previous study ([@B66]). There were 57 proteins that were not identified previously and these spots were excised from the gel and identified by mass spectrometry (Supplementary Table [S1](#SM2){ref-type="supplementary-material"} and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

OPLS Models
-----------

In total, seven OPLS models were created to analyze the correlation between expressed plasma proteins and NRS, HADS-total, BMI, and age in CWP and CON. The following protein distributions in all models were found -- metabolic: CWP = 41% and CON = 35%; immunity: CWP = 30% and CON = 37%; iron ion homeostasis: CWP = 8% and CON = 8%; inflammatory: CWP = 4% and CON = 15%; lipid metabolism: CWP = 18% and CON = 3%; and unknown processes: CWP = 0% and CON = 2%.

Plasma Proteins in Relation to Pain Intensity (NRS) in the CWP Group
--------------------------------------------------------------------

The OPLS model of NRS (NRS~CWP~) consisted of one predictive and one orthogonal component with a high sensitivity (*R*^2^ = 0.97), predictivity (*Q*^2^ = 0.85), and a significant CV-ANOVA (*p*-value \< 0.001). A total of 20 proteins had a VIP value \>1.0 and were considered significant regressors for NRS (*Y*-variable) in the CWP (Figure [1A](#F1){ref-type="fig"}). In the score plot of NRS~CWP~ (Figure [1B](#F1){ref-type="fig"}), a separation within the group is seen based on the respective NRS value, representing mild (0--3), moderate (4--6), and severe (7--10) pain intensity. The majority of the significant proteins belonged to metabolic and immunity processes, and other proteins belonged to lipid metabolism, iron ion homeostasis, and inflammatory processes (Table [2](#T2){ref-type="table"}).

![Orthogonal partial least squares regression analysis model of NRS in CWP. **(A)** Loading plot showing proteins with VIP value \>1.0 significantly associated to pain intensity, e.g., fibrinogen gamma chain, ceruloplasmin, and plasminogen. The proteins are grouped based on biological process. **(B)** Score plot illustrating separation within the CWP group based on reported pain intensity: mild (0--3), moderate (4--6), and severe (7--10). NRS, numeric rating scale; CWP, chronic widespread pain; OPLS, orthogonal partial least squares regression analysis.](fpsyg-09-02400-g001){#F1}

###### 

Orthogonal partial least squares regression analysis model of pain intensity (NRS) in CWP group.

  Spot number   Protein name                           Accession number   Biological process         Experimental MW (kDa)/p*I*   VIP        p(corr)     OD CON (Mean ± SD)     OD CWP (Mean ± SD)     OD quotient mean   Alteration CWP vs. CON
  ------------- -------------------------------------- ------------------ -------------------------- ---------------------------- ---------- ----------- ---------------------- ---------------------- ------------------ ------------------------
  **3817**      **Ceruloplasmin**                      **P00450**         **Iron ion homeostasis**   **163 / 5.41**               **1.40**   **0.74**    **62** ± **103**       **184** ± **161**      **2.97**           **↑**
  **4304**      **Fibrinogen gamma chain**             **P02679**         **Metabolic**              **71 / 5.66**                **1.32**   **0.64**    **16721** ± **6137**   **25746** ± **8738**   **1.54**           **↑**
  **2701**      **Alpha-1B-glycoprotein**              **P04217**         **Metabolic**              **109 / 5.32**               **1.26**   −**0.55**   **1539** ± **558**     **1622** ± **361**     **1.05**           **↑**
  **4302**      **Fibrinogen gamma chain**             **P02679**         **Metabolic**              **71 / 5.58**                **1.19**   **0.61**    **11371** ± **3908**   **17521** ± **5893**   **1.54**           **↑**
  **510**       **Kininogen-1**                        **P01042**         **Metabolic**              **87 / 4.88**                **1.18**   **0.52**    **440** ± **560**      **854** ± **725**      **1.94**           **↑**
  8822          Plasminogen                            P00747             Metabolic                  143 / 6.91                   1.15       0.55        430 ± 292              745 ± 337              1.73               **↑**
  1052          Apolipoprotein C-III                   P02656             Lipid metabolism           8 / 4.22                     1.15       0.58        774 ± 910              1013 ± 1355            1.31               **↑**
  9901          Plasminogen                            P00747             Metabolic                  143 / 7.11                   1.14       0.54        570 ± 332              763 ± 313              1.34               **↑**
  4809^∗^       Complement C1r subcomponent            P00736             Immunity                   132 / 5.58                   1.13       0.52        158 ± 101              238 ± 155              1.51               **↑**
  8909          Plasminogen                            P00747             Metabolic                  151 / 6.65                   1.12       0.57        322 ± 203              618 ± 375              1.92               **↑**
  2116^∗^       Transthyretin                          P02766             Iron ion homeostasis       13 / 4.75                    1.10       −0.57       3497 ± 2539            1265 ± 1382            0.36               **↓**
  4316^∗^       Haptoglobin                            P00738             Inflammatory               60 / 5.47                    1.10       −0.51       12243 ± 5754           12341 ± 7702           1.01               **↑**
  4807          Secretory immunoglobulin chain alpha   P99003             Immunity                   125 / 5.51                   1.09       0.51        114 ± 101              149 ± 117              1.31               **↑**
  9208          Fibrinogen alpha chain fragment        P02671             Metabolic                  40 / 8.07                    1.09       −0.61       509 ± 315              504 ± 390              0.99               **↓**
  4810          Complement C1r subcomponent            P00736             Immunity                   132 / 5.63                   1.07       0.50        247 ± 174              569 ± 239              2.30               **↑**
  2903^∗^       Alpha-1 -antitrypsin                   P01009             Metabolic                  151 / 5.32                   1.06       0.58        57 ± 111               70 ± 47                1.23               **↑**
  2604          Alpha-2 -antiplasmin                   P08697             Metabolic                  103 / 5.36                   1.05       0.48        166 ± 185              265 ± 212              1.60               **↑**
  4713          Secretory immunoglobulin chain alpha   P99003             Immunity                   125 / 5.47                   1.05       0.43        135 ± 124              129 ± 119              0.96               **↓**
  114           Clusterin                              P10909             Lipid metabolism           46 / 4.99                    1.05       −0.54       1879 ± 1725            1621 ± 921             0.86               **↓**
  2904          Alpha-1 -antitrypsin                   P01009             Metabolic                  151 / 5.36                   1.04       0.57        64 ± 97                99 ± 67                1.55               **↑**

20 proteins had a VIP \> 1. The proteins with highest VIP value (bold) were considered as important regressors for the model and belongs to metabolic and Iron ion homeostasis processes.

∗

Shared proteoforms with OPLS model of BMI

CON

and Age

CON

. NRS, numeric rating scale; SD, standard deviation; CON, control; CWP, chronic widespread pain; OD, optical density; MW, molecular weight; pI, isoelectric point; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.

The five proteins with the highest VIP values (VIP \> 1.18) and strongest associations with NRS were ceruloplasmin (iron ion homeostasis process), alpha-1B-glycoprotein, kininogen-1, and two proteoforms of fibrinogen gamma chain (metabolic processes) (Table [2](#T2){ref-type="table"}). These proteoforms are shown on a 2-DE gel (marked in black) to visualize the plasma protein pattern and the quantified intensity from individual samples in each group (Figure [2](#F2){ref-type="fig"}). The spot numbers on the gel correspond to the spot numbers in Table [2](#T2){ref-type="table"}.

![Plasma protein pattern and significant proteoforms from the OPLS models of NRS and HADS-total CWP. The preparative 2-DE gel (used for protein identification) was used to visualize the plasma proteome. Marked proteoforms represent the five most important proteins with highest VIP value for the OPLS model in NRS (marked in black) and HADS-total in CWP (marked in red). The quantified intensity (*Y*-axis) of the proteoform in individual samples (*X*-axis) in CWP and CON group is illustrated in the diagrams. The numbers refer to equal numbers in each table of the respective model. NRS, numeric rating scale; CWP, chronic widespread pain; CON, control; HADS, hospital anxiety and depression scale; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis; PPM, part per million.](fpsyg-09-02400-g002){#F2}

Plasma Proteins Versus HADS-Total
---------------------------------

### CWP

The OPLS model for HADS (HADS~CWP~) consisted of one predictive and one orthogonal component with a high sensitivity (*R*^2^ = 0.96), predictivity (*Q*^2^ = 0.70), and a significant CV-ANOVA (*p*-value = 0.011).

A total of 18 proteins had a VIP value \>1.0 and were considered significant regressors for HADS-total (*Y*-variable) in the CWP group (Figure [3A](#F3){ref-type="fig"}). In the score plot of HADS~CWP~, a within group separation is seen among CWP based on the reported HADS-total score (Figure [3B](#F3){ref-type="fig"}), representing normal (0--14), mild (15--20), and moderate (21--28) psychological distress.

![Orthogonal partial least squares regression analysis model HADS-total in the CWP. **(A)** Loading plot corresponding to proteins with a VIP value \>1.0 associated to psychological distress are illustrated. The proteins with strongest association to psychological distress are the immunity proteins complement factor B and complement C1r subcomponent and the iron ion homeostasis protein hemopexin. **(B)** Score plot showing a within group separation among CWP based on reported HADS-total score. The plot shows that CWP patients are grouped as normal (0--14), mild (15--20), and moderate (21--28) psychological distress. CWP, chronic widespread pain; HADS, hospital anxiety and depression scale; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.](fpsyg-09-02400-g003){#F3}

Among the important proteins, the majority of the proteins belonged to immunity processes. Other proteins belonged to inflammatory processes, iron ion homeostasis, lipid metabolism, and metabolic processes (Table [3](#T3){ref-type="table"}).

###### 

Orthogonal partial least squares regression analysis model of CWP HADS-total.

  Spot number   Protein Name                        Accession number   Biological process         Experimental MW (kDa)/p*I*   VIP        p(corr)     OD CON (Mean ± SD)     OD CWP (Mean ± SD)     OD quotient mean   Alteration CWP vs. CON
  ------------- ----------------------------------- ------------------ -------------------------- ---------------------------- ---------- ----------- ---------------------- ---------------------- ------------------ ------------------------
  **1104**      **Clusterin**                       **P10909**         **Lipid metabolism**       **44 / 5.03**                **1.36**   −**0.71**   **1649** ± **1628**    **1190** ± **912**     **0.72**           **↓**
  **4604**      **Hemopexin**                       **P02790**         **Iron ion homeostasis**   **105 / 5.69**               **1.29**   **0.68**    **13505** ± **2499**   **13650** ± **3143**   **1.01**           **↑**
  **7901**      **Complement factor B**             **P00751**         **Immunity**               **140 / 6.29**               **1.28**   **0.66**    **1018** ± **515**     **1216** ± **395**     **1.19**           **↑**
  **5819**      **Complement C1r subcomponent**     **P00736**         **Immunity**               **137 / 5.66**               **1.27**   **0.71**    **81** ± **110**       **241** ± **155**      **2.98**           **↑**
  **3214**      **Clusterin**                       **P10909**         **Lipid metabolism**       **42 / 5.26**                **1.23**   −**0.61**   **355** ± **312**      **175** ± **135**      **0.49**           **↓**
  6839          Serotransferrin                     P02787             Iron ion homeostasis       130 / 6.13                   1.21       −0.68       979 ± 458              1078 ± 460             1.10               **↑**
  6845          Complement component C7             P10643             Immunity                   148 / 6.11                   1.21       −0.63       208 ± 277              256 ± 197              1.23               **↑**
  1414          Leucine-rich alpha-2-glycoprotein   P02750             Immunity                   67 / 4.88                    1.14       −0.62       390 ± 202              371 ± 322              0.95               **↓**
  1051          Apolipoprotein C-II                 P02655             Lipid metabolism           7 / 4.40                     1.14       −0.61       483 ± 496              882 ± 893              1.83               **↑**
  7819          Plasminogen                         P00747             Metabolic                  143 / 6.73                   1.13       −0.60       325 ± 224              524 ± 280              1.61               **↑**
  114           Clusterin                           P10909             Lipid metabolism           46 / 4.99                    1.12       −0.61       1879 ± 1725            1621 ± 921             0.86               **↓**
  1113          Clusterin                           P10909             Lipid metabolism           45 / 5.17                    1.11       −0.65       1501 ± 1437            1545 ± 1275            1.03               **↑**
  1416          Leucine-rich alpha-2-glycoprotein   P02750             Immunity                   69 / 4.70                    1.11       −0.55       248 ± 217              299 ± 443              1.21               **↑**
  7120^∗^       Ig kappa chain C region             P01834             Immunity                   28 / 6.29                    1.08       −0.59       7997 ± 4977            6563 ± 6880            0.82               **↓**
  3408          Vitamin D-binding protein           P02774             Inflammatory               82 / 5.45                    1.05       −0.62       404 ± 270              530 ± 286              1.31               **↑**
  8306          Chitinase-3-like protein 1          P36222             Inflammatory               54 / 7.11                    1.05       −0.53       288 ± 552              276 ± 704              0.96               **↓**
  4503          Ig alpha-2 chain C region           P01877             Immunity                   90 / 5.66                    1.05       0.56        10969 ± 4475           6430 ± 3878            0.59               **↓**
  6608          Hemopexin                           P02790             Iron ion homeostasis       98 / 5.83                    1.03       0.56        1991 ± 657             2157 ± 555             1.08               **↑**

Proteins with highest VIP values are marked in bold.

∗

Shared proteoforms with OPLS model of Age

CON

. HADS, hospital anxiety and depression scale; SD, standard deviation; CON, control; CWP, chronic widespread pain; OD, optical density; MW, molecular weight; pI, isoelectric point; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.

The five proteins with highest VIP value (VIP \> 1.23) were one upregulated proteoform of complement C1r subcomponent (immunity process), complement factor B (immunity process), and hemopexin (iron ion homeostasis process) and two down regulated proteoforms of clusterin (lipid metabolism process) (Table [3](#T3){ref-type="table"}). These proteoforms are shown on the 2-DE gel (marked in red) with quantified intensity from individual samples in each group (Figure [2](#F2){ref-type="fig"}). The spot numbers correspond to spot numbers in Table [3](#T3){ref-type="table"}.

### CON

The OPLS model for CON of HADS-total (HADS~CON~) had one predictive component and one orthogonal component with good sensitivity (*R*^2^ = 0.84), moderate predictivity (*Q*^2^ = 0.48), and a significant CV-ANOVA (*p*-value = 0.016). A total of 12 proteins had a VIP value \>1.0 and were considered significant important regressors for HADS (*Y*-variable) in the CON group. The identified proteins belonged to metabolic, immunity, inflammatory and unknown function, where majority of the proteins were metabolic proteins. For more details, see Supplementary Figure [S2](#SM1){ref-type="supplementary-material"} and Supplementary Table [S2](#SM3){ref-type="supplementary-material"}.

OPLS Models of BMI in CON and CWP
---------------------------------

### CON

To evaluate the correlation of BMI and expressed plasma proteins, an OPLS model of BMI in the CON group (BMI~CON~) was analyzed. The OPLS model for BMI~CON~ consisted of one predictive and one orthogonal component with good sensitivity (*R*^2^ = 0.85), lower predictivity (*Q*^2^ = 0.42), and a significant CV-ANOVA (*p*-value = 0.038).

A total of 31 proteins had a VIP value \>1.0 and were considered significant important regressors for BMI (*Y*-variable) in the CON group (Figure [4](#F4){ref-type="fig"}). The majority of the proteins belonged to immunity and metabolic processes.

![Orthogonal partial least squares regression analysis model BMI in CON. Loading plot illustrating proteins with a VIP value \>1.0 associated with BMI. The majority of the proteins belonged to immunity and metabolic responses. Several inflammatory proteins were also present. OPLS, orthogonal partial least squares regression analysis; VIP, variable influence on projection; CON, control; BMI, body mass index.](fpsyg-09-02400-g004){#F4}

The proteins with highest VIP values (VIP \> 1.40) were two upregulated proteoforms of haptoglobin (inflammatory process) and one proteoform each of alpha-1-antitrypsin, plasminogen, and serum amyloid P-component (metabolic processes) (Table [4](#T4){ref-type="table"}).

###### 

Orthogonal partial least squares regression analysis model of CON and BMI.

  Spot number   Protein name                            Accession number   Biological process     Experimental MW (kDa)/p*I*   VIP        p(corr)     OD CON (Mean ± SD)     OD CWP (Mean ± SD)     OD quotient mean   Alteration CWP vs. CON
  ------------- --------------------------------------- ------------------ ---------------------- ---------------------------- ---------- ----------- ---------------------- ---------------------- ------------------ ------------------------
  **4119**      **Serum amyloid P-component**           **P02743**         **Metabolic**          **27 / 5.63**                **1.48**   **0.64**    **950** ± **974**      **1474** ± **1330**    **1.55**           **↑**
  **4104**      **Haptoglobin**                         **P00738**         **Inflammatory**       **53 / 5.74**                **1.45**   **0.75**    **2265** ± **1193**    **3233** ± **1194**    **1.43**           **↑**
  **3420**      **Alpha-1- antitrypsin**                **P01009**         **Metabolic**          **71 / 5.26**                **1.44**   −**0.62**   **10036** ± **6237**   **12878** ± **9795**   **1.28**           **↑**
  **1204**      **Haptoglobin**                         **P00738**         **Inflammatory**       **62 / 5.26**                **1.42**   **0.67**    **10232** ± **6356**   **12766** ± **7283**   **1.25**           **↑**
  **8910**      **Plasminogen**                         **P00747**         **Metabolic**          **151 / 6.73**               **1.40**   **0.61**    **463** ± **237**      **752** ± **341**      **1.62**           **↑**
  4316          Haptoglobin                             P00738             Inflammatory           61 / 5.63                    1.40       0.75        12243 ± 5754           12341 ± 7702           1.01               **↑**
  1111          Complement factor I light chain         P05156             Immunity               48 / 5.22                    1.33       0.61        293 ± 273              786 ± 333              2.68               **↑**
  5818          Complement C1r subcomponent             P00736             Immunity               137 / 5.63                   1.33       0.54        59 ± 94                222 ± 184              3.76               **↑**
  145           Complement C3c alpha chain fragment 2   P01024             Immunity               50 / 5.03                    1.28       0.62        360 ± 299              869 ± 312              2.41               **↑**
  5723          C4b-binding protein alpha chain         P04003             Immunity               116 / 5.80                   1.26       0.59        296 ± 422              545 ± 425              1.84               **↑**
  5825          Complement C1r subcomponent             P00736             Immunity               130 / 5.66                   1.25       0.61        246 ± 144              490 ± 192              1.99               **↑**
  8901          Plasminogen                             P00747             Metabolic              143 / 7.02                   1.24       0.56        796 ± 561              1000 ± 438             1.26               **↑**
  3709          Alpha-1B -glycoprotein                  P04217             Metabolic              111 / 5.30                   1.23       −0.49       600 ± 316              508 ± 301              0.85               **↓**
  4808          Secretory immunoglobulin chain alpha    P99003             Immunity               125 / 5.54                   1.22       0.65        96 ± 110               88 ± 91                0.92               **↓**
  5833          Hemopexin                               P02790             Iron ion homeostasis   169 / 5.69                   1.21       0.70        78 ± 54                105 ± 104              1.35               **↑**
  8101          Complement C4-B                         P0C0L5             Immunity               45 / 6.35                    1.20       0.61        2511 ± 1437            3344 ± 1364            1.33               **↑**
  2116          Transthyretin                           P02766             Iron ion homeostasis   13 / 4.75                    1.20       −0.36       3497 ± 2539            1265 ± 1382            0.36               **↓**
  4809          Complement C1r subcomponent             P00736             Immunity               132 / 5.58                   1.19       0.63        158 ± 101              238 ± 155              1.51               **↑**
  8823          Plasminogen                             P00747             Metabolic              151 / 6.91                   1.17       0.56        319 ± 211              652 ± 318              2.04               **↑**
  2202          Alpha-1 -antitrypsin                    P01009             Metabolic              69 / 5.36                    1.15       −0.46       3372 ± 1579            2829 ± 2183            0.84               **↓**
  2903          Alpha-1 -antitrypsin                    P01009             Metabolic              151 / 5.32                   1.12       0.50        57 ± 111               70 ± 47                1.23               **↑**
  6713          C4b-binding protein alpha chain         P04003             Immunity               116 / 5.88                   1.11       0.53        212 ± 250              438 ± 378              2.07               **↑**
  9522          Complement C4-B beta chain              P0C0L5             Immunity               90 / 8.65                    1.10       0.54        284 ± 484              584 ± 860              2.06               **↑**
  1806          Complement C1s subcomponent             P09871             Immunity               127 / 5.09                   1.09       0.53        259 ± 355              626 ± 359              2.42               **↑**
  6324          Ficolin-3                               O75636             Immunity               47 / 6.00                    1.07       0.45        313 ± 271              617 ± 338              1.97               **↑**
  3606          Alpha-2 -antiplasmin                    P08697             Metabolic              109 / 5.38                   1.06       −0.53       187 ± 138              168 ± 211              0.90               **↓**
  5824          Complement C1r subcomponent             P00736             Immunity               135 / 5.69                   1.05       0.59        162 ± 94               278 ± 129              1.72               **↑**
  3809          Alpha-1 -antitrypsin                    P01009             Metabolic              148 / 5.22                   1.05       0.51        116 ± 161              96 ± 109               0.83               **↓**
  3209          Haptoglobin beta chain                  P00738             Inflammatory           48 / 5.36                    1.03       0.50        210 ± 171              393 ± 186              1.87               **↑**
  7216          Complement C4-B                         P0C0L5             Immunity               46 / 6.13                    1.02       0.61        865 ± 723              1001 ± 920             1.16               **↑**
  131           Clusterin                               P10909             Lipid metabolism       47 / 4.99                    1.02       −0.50       1050 ± 539             1147 ± 806             1.09               **↑**

31 proteins had a VIP \> 1. The proteins with highest VIP belongs to metabolic and inflammatory processes (marked in bold) and was considered as most important for the model. BMI, body mass index; SD, standard deviation; CON, control; CWP, chronic widespread pain; OD, optical density; MW, molecular weight; pI, isoelectric point; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.

### CWP

The OPLS model of BMI for CWP (BMI~CWP~) consisted of one predictive and one orthogonal component with high sensitivity (*R*^2^ = 0.92), predictivity (*Q*^2^ = 0.70), and significant CV-ANOVA (*p*-value = 0.011). A total of 21 proteins had a VIP value \>1.0 and were considered significant important regressors for BMI (*Y*-variable) in the CWP group. The identified proteins belonged to immunity, lipid metabolism, and metabolic processes. For more details, see Supplementary Figure [S3](#SM1){ref-type="supplementary-material"} and Supplementary Table [S3](#SM3){ref-type="supplementary-material"}.

OPLS Models of Age in CON and CWP
---------------------------------

### CON

To evaluate the influence of age on the expressed plasma proteins, an OPLS model of age in CON (Age~CON~) was analyzed. The OPLS model Age~CON~ had one predictive and one orthogonal component and showed high sensitivity (*R*^2^ = 0.89), predictivity (*Q*^2^ = 0.76), and a significant CV-ANOVA (*p*-value \< 0.001). A total of 19 proteins had a VIP value \>1.0 and were considered significant important regressors for age (*Y*-variable) in the CON group (Figure [5](#F5){ref-type="fig"}). Proteins belonging to immunity, inflammatory, iron ion homeostasis, lipid metabolism, and metabolic processes were present.

![Orthogonal partial least squares regression analysis model of age in CON. Loading plot illustrating proteins with a VIP value \>1.0. A variety of different protein groups were present, and proteins with highest VIP value and strongest association to age were one proteoform of haptoglobin and antithrombin-III. OPLS, orthogonal partial least squares regression analysis; VIP, variable influence on projection; CON, control; BMI, body mass index.](fpsyg-09-02400-g005){#F5}

The five proteins with highest VIP values (VIP \> 1.28) were two upregulated proteoforms of fibrinogen alpha chain (metabolic process) and one proteoform of haptoglobin (inflammatory process). One proteoform of Ig alpha-2 chain C region (immunity process) and antithrombin-III (metabolic process) was downregulated (Table [5](#T5){ref-type="table"}).

###### 

Orthogonal partial least squares regression analysis model of CON and Age.

  Spot number   Protein Name                    Accession number   Biological process     Experimental MW (kDa)/p*I*   VIP        p(corr)     OD CON (Mean ± SD)    OD CWP (Mean ± SD)    OD quotient mean   Alteration CWP vs. CON
  ------------- ------------------------------- ------------------ ---------------------- ---------------------------- ---------- ----------- --------------------- --------------------- ------------------ ------------------------
  **6505**      **Ig alpha-2 chain C region**   **P01877**         **Immunity**           **94 / 6.02**                **1.53**   −**0.62**   **2614** ± **1651**   **1772** ± **1267**   **0.68**           **↓**
  **3406**      **Antithrombin-III**            **P01008**         **Metabolic**          **76 / 5.54**                **1.52**   **0.65**    **1243** ± **671**    **973** ± **734**     **0.78**           **↓**
  **8618**      **Fibrinogen alpha chain**      **P02671**         **Metabolic**          **105 / 7.47**               **1.51**   −**0.65**   **2045** ± **808**    **2365** ± **1147**   **1.16**           **↑**
  **5319**      **Haptoglobin**                 **P00738**         **Inflammatory**       **54 / 5.88**                **1.28**   **0.60**    **388** ± **232**     **456** ± **539**     **1.18**           **↑**
  **8719**      **Fibrinogen alpha chain**      **P02671**         **Metabolic**          **107 / 7.11**               **1.28**   −**0.53**   **3726** ± **1058**   **4040** ± **1837**   **1.08**           **↑**
  6407          Beta-2-glycoprotein 1           P02749             Lipid metabolism       81 / 6.00                    1.27       0.60        567 ± 125             651 ± 299             1.15               **↑**
  7120          Ig kappa chain C region         P01834             Immunity               28 / 6.29                    1.23       −0.47       7997 ± 4977           6563 ± 6880           0.82               **↓**
  4316          Haptoglobin                     P00738             Inflammatory           61 / 5.47                    1.20       0.54        12243 ± 5754          12341 ± 7702          1.01               **↑**
  2601          Alpha-1B -glycoprotein          P04217             Metabolic              107 / 5.36                   1.19       0.54        3245 ± 838            3063 ± 434            0.94               **↓**
  7743          Serotransferrin                 P02787             Iron ion homeostasis   120 / 6.29                   1.18       −0.54       32454 ± 8480          26409 ± 6738          0.81               **↓**
  6114          Ig kappa chain C region         P01834             Immunity               28 / 6.05                    1.12       −0.41       1733 ± 2089           640 ± 883             0.37               **↓**
  6840          Complement C3 alpha chain       P01024             Immunity               157 / 6.08                   1.09       0.54        386 ± 169             614 ± 904             1.59               **↑**
  5821          Alpha-2 -macroglobulin          P01023             Immunity               176 / 5.71                   1.08       −0.49       407 ± 228             579 ± 284             1.42               **↑**
  3105          Haptoglobin                     P00738             Inflammatory           54 / 5.47                    1.05       0.45        2076 ± 1223           2770 ± 1183           1.33               **↑**
  2202          Alpha-1 -antitrypsin            P01009             Metabolic              69 / 5.36                    1.04       −0.43       3372 ± 1579           2829 ± 2183           0.84               **↓**
  6731          Serotransferrin                 P02787             Iron ion homeostasis   130 / 6.25                   1.03       −0.32       2008 ± 714            1798 ± 710            0.90               **↓**
  4833          Ceruloplasmin                   P00450             Iron ion homeostasis   163 / 5.51                   1.02       0.37        81 ± 109              219 ± 160             2.70               **↑**
  2203          Haptoglobin                     P00738             Inflammatory           61 / 5.36                    1.02       0.44        12006 ± 6246          16032 ± 7681          1.34               **↑**
  4301          Fibrinogen gamma chain          P02679             Metabolic              72 / 5.47                    1.00       0.50        4565 ± 2265           6308 ± 3044           1.38               **↑**

19 proteins had a VIP \> 1. The 5 proteins with highest VIP values (bold marking) is considered as most important regressor for the model and belonged to immunity, inflammatory and metabolic processes. SD, standard deviation; CON, control; CWP, chronic widespread pain; OD, optical density; MW, molecular weight; pI, isoelectric point; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.

### CWP

The OPLS model of Age in CWP (Age~CWP~) had one predictive and one orthogonal component and showed high sensitivity (*R*^2^ = 0.94), predictivity (*Q*^2^ = 0.77), and a significant CV-ANOVA (*p*-value = 0.003). A total of 12 proteins had a VIP value \>1.0 and were considered significant important regressors for age (*Y*-variable) in the CWP group. Proteins belonging to immunity, iron ion homeostasis, lipid metabolism, and metabolic processes were present. For more details, see Supplementary Figure [S4](#SM1){ref-type="supplementary-material"} and Supplementary Table [S4](#SM3){ref-type="supplementary-material"}.

Shared Proteoforms -- Compensating for Possible Cofounding Effects of Age and BMI
---------------------------------------------------------------------------------

To avoid possibly confounding effects of age and BMI on NRS and HADS-total, we compared the models of age and BMI in CON with the models of NRS and HADS-total in CWP. Shared proteoforms were eliminated from the models of NRS~CWP~ and HADS~CWP~, and the models were recalculated.

In the OPLS models of BMI~CON~ and Age~CON~, four proteoforms with a VIP \>1.0 (spot number 2116, 2903, 4316, and 4809) were also present in the NRS~CWP~ model. These proteoforms were excluded from the obtained NRS~CWP~ model and the model was re-calculated. The new also significant OPLS model of NRS~CWP~ only had slightly changed parameters (*R*^2^ = 0.96, *Q*^2^ = 0.84, CV-ANOVA; *p* \< 0.001) and 16 proteins with a VIP \> 1.0 (the same proteins as in first model).

One proteoform (spot number 7120) was shared between the OPLS model of Age~CON~ and HADS~CWP~. No proteoforms were shared between BMI~CON~ and HADS~CWP~. To investigate whether age had a possible cofounding effect on HADS in the models, the shared proteoform was excluded from HADS~CWP~ and a new model was calculated. The new resulting OPLS model for HADS~CWP~ was very similar to the first (*R*^2^ = 0.96, *Q*^2^ = 0.66, CV-ANOVA; *p* \< 0.05), with a slightly lower *R*^2^-value and with the same proteins as important regressors with a VIP \> 1.0.

Compensating for Possible Cofounding Effects of HADS-Total Upon NRS~CWP~
------------------------------------------------------------------------

After comparing the OPLS models of NRS~CWP~ and HADS~CWP~, one proteoform (spot number 114) was shared and therefore excluded in both models. The new model of NRS~CWP~ (*R*^2^ = 0.96, *Q*^2^ = 0.84, CV-ANOVA; *p* \< 0.001) and HADS~CWP~ (*R*^2^ = 0.96, *Q*^2^ = 0.66, CV-ANOVA; *p* \< 0.05) had unchanged parameters compared to previous ones.

Other Shared Proteoforms
------------------------

In total, 16 proteoforms were shared among other OPLS models. One proteoform of alpha-1-antitrypsin (spot number 2904) was shared between OPLS model NRS~CWP~ and Age~CWP~, and one proteoform of alpha-1-antitrypsin (spot number 2202) was shared between models BMI~CON~ and Age~CON~. Furthermore, two proteoforms of clusterin were shared among Age~CWP~ and BMI~CON~ (spot number 131) and HADS~CWP~ and Age~CWP~ (spot number 1113). Two proteoforms of complement C4-B (spot number 7216 and 8101) was shared between HADS~CON~ and BMI~CON~. Fibrinogen alpha chain (spot number 8719) was shared between Age~CON~ and BMI~CWP~. Fibrinogen gamma chain (spot number 4302 and 4304) was present in both NRS~CWP~ and BMI~CWP~. One proteoform N-acetylmuramoyl-L-alanine amidase (spot number 5721) was present in Age~CWP~ and BMI~CWP~. Three proteoforms of plasminogen were present in several OPLS models: HADS~CWP~ and HADS~CON~ (spot number 7819) and NRS~CWP~ and HADS~CON~ (spot number 8822 and 8909). Two proteoforms of secretory immunoglobulin chain alpha (spot number 4713 and 4807) was present in NRS~CWP~ and BMI~CWP~. Finally, one proteoform of complement factor I light chain (spot number 1111) was present in Age~CWP~ and BMI~CON~ models.

Discussion
==========

The following are the major results in this present exploratory proteomic study of the plasma in CWP:

1.  Pain intensity in CWP was associated with several plasma proteins involved in metabolic and immunity processes such as kininogen-1, fibrinogen gamma chain, and ceruloplasmin.

2.  Psychological distress in CWP was associated with plasma proteins related to immunity response and iron ion metabolism such as complement factor B, complement C1r subcomponent, and hemopexin.

3.  Proteomics in combination with multivariate statistics can be used to analyze associations between plasma proteins and pain intensity, psychological distress, BMI, and age in CWP and CON.

Overall, investigating the plasma proteome and proteins associated with different clinical measurements, as exemplified in this study, reveals different protein patterns for pain intensity and psychological distress. MVDA is commonly used in proteomic studies to analyze complex biofluids such as urine, plasma, serum, and CSF from CWP ([@B32]; [@B3],[@B4]; [@B46]; [@B66]). By including the analysis of BMI and age, possible cofounding effects on proteins in each specific model has been evaluated with no major changes in the stability (goodness of fit and model prediction) of pain intensity or psychological distress models. Investigations of the plasma proteome in patients with CWP and/or fibromyalgia have been limited. To the best of our knowledge, no studies have investigated the relationship between pain intensity and psychological distress and the plasma proteome profile.

Pain Intensity and Plasma Proteins
----------------------------------

Pain intensity is an important facet of perception of pain in chronic pain patients. Increased pain intensity is a common feature among CWP patients ([@B20]) and, as expected, was relatively high in CWP. The most important proteins that showed the strongest association to pain intensity were upregulated proteoforms of ceruloplasmin, fibrinogen gamma chain, alpha-1B-glycoprotein, and kininogen-1 (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

Based on the interpretation of the score plot in combination with the loading plot for NRS~CWP~ (Figures [1A,B](#F1){ref-type="fig"}), the proteoform of alpha-1B-glycoprotein (one of the top five proteins with a VIP \> 1) was associated with lower pain intensity, whereas the other proteins were associated with higher pain intensity (Figure [1A](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Interestingly, when analyzing NRS~CWP~, the CWP group was divided into subgroups in the score plot according to their reported pain intensity (Figure [1B](#F1){ref-type="fig"}), reflecting the proteins displayed in each loading plot (Figure [1A](#F1){ref-type="fig"}). This subdivision within the CWP group could be the result of greater pain intensity being associated with specific metabolic and immunity proteins, which in turn reflects different ongoing protein responses. To test this hypothesis, future studies should analyze CWP patients with severe pain intensity (NRS score \>7).

Fibrinogen (comprised of fibrinogen alpha, beta, and gamma chain) and kinogen-1 are known to be involved in different aspects of the blood coagulation cascade ([@B51]; [@B61]; [@B71]). Kininogen-1 is primarily involved in the kallikrein-kinin system, and after cleavage one of its products triggers release of bradykinin. Bradykinin is a known mediator of pain ([@B67]), which further activates the inflammatory response through its indirect production of nitric oxide (NO) and induction of prostaglandins ([@B13]). Kininogen-1 and bradykinin expressions were altered in the synovial fluid of rheumatoid arthritis and osteoarthritis patients ([@B48]; [@B71]). Kiniogen-1 has also been found to be elevated in the plasma of farmers with musculoskeletal disorders ([@B28]). In this study, both proteoforms of fibrinogen gamma chain and kininogen-1 were upregulated in CWP in the NRS~CWP~ model, which could indicate an increase in inflammatory response.

Ceruloplasmin, an acute-phase protein, is one of the largest transport proteins for copper ions ([@B34]). To the best of our knowledge, no direct connection between ceruloplasmin and pain intensity has been reported. Elevated levels of ceruloplasmin have been found in fibromyalgia patients compared to controls, ([@B39]) suggesting altered regulation of copper metabolism may be involved in the pathophysiology of FMS. In our previous plasma proteomic study, we found several proteoforms of ceruloplasmin to be altered and associated with CWP compared to CON ([@B66]). One of the proteoforms of ceruloplasmin (spot number 3817), found in previous work, was also seen in this study. From the following in-depth analysis, we found that the specific ceruloplasmin proteoform was specifically associated with increased pain intensity.

By studying changes of proteins both systemically and peripherally in the trapezius muscle, the molecular signature and potential biomarkers of pain can be analyzed. For example, from the same cohort different proteoforms of alpha-1-antitrypsin have been found significantly altered in the interstitial fluid of trapezius muscle, a finding confirmed in this study ([@B53]). One of the proteoforms of alpha-1-antitrypsin (spot number 2904) was increased and associated with pain intensity; however, the proteoforms from each study had different experimental molecular weights and p*I* (isoelectric point), which could be due to post-translational modifications (PTMs), although this has not been analyzed in detail and needs to be confirmed. The involvement of alpha-1-antitrypsin in fibromyalgia has been reviewed earlier ([@B9]), suggesting that it is involved and in favor of an inflammatory response in fibromyalgia patients.

The majority of proteins with a significant association with pain intensity belonged to metabolic processes (according to the UniProt Database). Metabolic proteins have been found to be significantly altered in the trapezius muscle from females with trapezius myalgia and CWP, ([@B33]; [@B56]) suggesting a change in energy metabolism in the muscle. These metabolic proteins seem peripherally and systemically important and involved in mechanisms maintaining CWP.

In summary, pain intensity was associated with plasma proteins involved in metabolic and immunity processes. The most significant proteins were upregulated in CWP. These proteins are known acute-phase protein (ceruloplasmin), which suggests an inflammatory response (fibrinogen and kininogen-1) and changes in energy metabolism.

Psychological Distress Correlates With Immunity Proteins
--------------------------------------------------------

The scores from both HADS-anxiety and depression were merged (HADS-total) to get an overall indication of psychological distress. There were significant higher scores in both subscales and HADS-total for CWP compared to CON (Table [1](#T1){ref-type="table"}). However, at the group level, both subscales were below the cut-off values of severe symptoms (≥11).

By interpreting the score plot in combination with the loading plot for HADS~CWP~, three of the proteins with highest VIP value were positively associated with psychological distress: complement factor B, complement C1r subcomponent, and hemopexin. Both proteoforms of clusterin were negatively associated with HADS-total in CWP (Figures [3A,B](#F3){ref-type="fig"}).

Different immune cells such as microglia cells and astrocytes in the brain and macrophages in the periphery can secrete inflammatory substances that in turn can affect peripheral nociceptors in chronic pain ([@B35], [@B36]). These nociceptors can generate action potentials that cause the release of specific ligands in the spinal cord that are ultimately processed by the central nervous system (CNS). They can also receive input and transmission from the CNS out to the periphery, causing local activation of immune cells ([@B12]). The concept of psychoneuroimmunology (PNI) describes a multifaceted interplay between psychological, endocrine, and immune systems, ([@B49]) which has been described to be involved in fibromyalgia ([@B50]). In this study, several of the proteins belonged to immunity process and the CWP group also had an increased psychological distress compared to CON. So far, no studies have investigated the relationship between psychological distress and plasma proteins in CWP. However, increase in pro-inflammatory cytokines and other inflammatory factors in plasma/serum from patients with depression have been reported in several studies ([@B17]; [@B16]). Plasma and serum proteomic studies of patients with major depressive disorders have found altered levels of acute phase, complement, and metabolic proteins similar to our study ([@B41]; [@B59]). These studies indicate that changed anxiety or depression status could affect proteins systemically. If this is the case in our study, this might be one explanation for the more immunity and inflammatory proteins seen in CWP. However, the expression of plasma proteins in CWP with severe psychological distress is not known (symptoms that are more related to patients with major depressive disorder), and this should be investigated in future studies.

Complement factor B and complement C1r subcomponent were both upregulated compared to CON and associated with higher HADS-total score in our study (Figures [2](#F2){ref-type="fig"}, [3A](#F3){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Complement factor B is essential for complement activation through the alternative pathway and activation of adaptive immune response. Complement proteins and coagulation proteins have been reported to be dysregulated in young children who later in life developed psychotic disorders ([@B18]).

Clusterin, also known as Apolipoprotein J, is a lipoprotein involved in several different cellular processes as lipid transportation, tissue remodeling, apoptosis and inflammation. Several proteoforms of clusterin were significantly altered and associated with higher psychological distress (Figure [3A](#F3){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Lower levels of serum clusterin has been found associated with pain in patients with hand osteoarthritis compared to healthy controls ([@B38]).

Hemopexin, the largest carrier protein for heme, is classified as an acute phase protein ([@B65]). Free excessive heme (i.e., not bound to hemopexin) can result in production of free radicals and oxidative stress and potentially tissue damage, leading to activation of macrophages, release of cytokines, and induction of inflammation ([@B58]). Increased hemopexin levels seen in the HADS~CWP~ model might indicate a protective effect related to a local antioxidant role ([@B31]).

In summary, psychological distress in CWP was associated with plasma proteins related to immunity response and iron ion metabolism. Among the most significant upregulated proteins were complement factor B, complement C1r subcomponent, and hemopexin. Immunity and coagulation proteins play a part in depression; ([@B62]; [@B42]), however, in this study, CWP at the group level did not exhibit severe symptoms of anxiety and depression (i.e., ≥11) ([@B75]). However, it is plausible that an increase in psychological distress in CWP can affect and even alter immunity proteins even more, which in turn can lead to more intense and prolonged inflammatory response.

Shared Proteoforms and Post-translational Modifications
-------------------------------------------------------

One of the advantages of using 2-DE is its ability to detect and investigate a protein's different proteoforms and its PTMs such as truncation, phosphorylation, and glycosylation. In this study, different proteoforms of the same protein were found differentially expressed in the different MVDA models. For example, four proteoforms of clusterin were differentially expressed -- one form was up-regulated and three were down regulated -- in the HADS~CWP~ model (Table [3](#T3){ref-type="table"}). Differentially charged proteoforms of clusterin in plasma have been reported ([@B28]). Findings like these are normally missed when using 1D or LC based proteomics. However, the physiological relevance of these different proteoforms in chronic pain have yet to be fully understood. Further studies to characterize the different proteoforms are needed before analysis with immunoassay such as western blot. By using immunoassay it is possible to detect/quantify the total amount of clusterin and to the best of our knowledge there are no commercial available antibodies against the different proteoforms of clusterin.

Glycosylated proteins may have a prolonged half-life time in circulation ([@B22]). If this is the case for several of the proteins found in this study, an overall increase of these proteins might contribute to a sustained inflammatory response. Furthermore, PTMs of ion channels involved in peripheral sensitization have been well-reviewed by [@B7] and [@B40] PTMs like phosphorylation of the capsaicin receptor (Transient receptor potential vanilloid 1, TRPV1) and sodium, potassium, and calcium channels expressed in primary sensory neurons can alter both the function and expression and thereby affect the transducing capability and excitability of the receptors. Although the proteins found in this study are not covered by these articles, PTMs are suggested to be involved in chronic pain. Therefore, future studies could use proteomics to detect different proteoforms with potential PTMs in different pain conditions of interest.

Shared Plasma Proteins in NRS~CWP~, HADS~CWP~, and OPLS-DA Model of CWP and CON
-------------------------------------------------------------------------------

In total among all models presented in this study, 21 proteins were seen in our previous study comparing group differences of plasma proteins between CWP and CON using OPLS-DA analysis ([@B66]). Specifically, six proteoforms (spot number 3817, 4304, 4302, 8822, 2116, and 4810) were shared among NRS~CWP~ and two proteoforms (5819 and 4503) in HADS~CWP~ compared to the OPLS-DA model of CWP and CON. Interestingly, in the NRS~CWP~ model four out of these six proteoforms (spot number 3817, 4302,4304, and 8822) are the proteoforms with highest VIP value (Table [2](#T2){ref-type="table"}). These proteins have been identified on both group levels with strong association to CWP and specifically related to pain intensity. In the previous study, transthyretin (spot number 2116) was more associated to CON, which is further shown in this study since it was found in BMI~CON~ (Table [4](#T4){ref-type="table"}) and therefore excluded in the NRS~CWP~ analysis. MVDA allows for the analysis of the protein patterns both on the group level, followed by in-depth analysis, and on its association to clinical parameters, which potentially could reflect the ongoing mechanisms involved in CWP.

Low-Grade Systemic Inflammation in CWP Patients
-----------------------------------------------

Using the same cohort, our recent analysis of the inflammatory cytokine/chemokine profile suggested a low-grade inflammation in CWP patients ([@B24]). The CSF proteome was analyzed in an additional cohort and showed that the proteins were involved in the immune system, apoptotic regulations, anti-inflammatory, and anti-oxidative processes, indicating presence of neuro-inflammation in the CNS of the CWP patients ([@B55]). These results are in line with the plasma profile seen in this study and were the most discriminant proteins belonging to immunity and metabolic responses highly involved in inflammatory processes.

Strengths and Limitations
-------------------------

The complexity of plasma sample or other biofluids and its limitation to detect all proteins or other metabolites with one single method remains difficult. However, one advantage with using traditional 2-DE is the interpretation of a protein's different proteoforms and potential PTMs, which has shown in this study to be of importance since a majority of the significant proteins are expressed as different proteoforms. Furthermore, 2-DE is limited in detecting large hydrophobic proteins (\>200 kDa) and small peptides (\<10 kDa). A gel's gradient composition and the resolution of proteins in the first dimension could also affect the number of detected proteins in each gel. In this study, removal of albumin and IgG from plasma was used as pre-treatment of the plasma sample. It is possible that the removal procedure might have eliminated some other candidates that could be of interest. Further studies using fractionation could be used to generate a data set with more protein identifications and improved confidence. The advantage of MVDA is its application on large scale data produced when using proteomics. We have shown that MVDA is highly applicable in the proteomic field of chronic pain both when comparing proteins on a group level and when interpreting clinical parameters and its association with plasma proteins.

The interpretation of the result in this study should be taken with precaution due to its small sample size. In future studies, sample size needs to be increased. However, due to restrict inclusion/exclusion criteria we -- in the context of chronic pain conditions -- has achieved a relatively homogenous group of CWP patients even though some degree of heterogeneity cannot be excluded. The recruitment of the subjects in the present study took place before the current revised ACR criteria of 2016 were accepted. In future larger studies -- during a transition period -- it may be an advantage to describe the patients using both the ACR criteria from 1990 and the revised criteria from 2016. Moreover, future studies should include CWP patients with high and low psychological distress as well as pain free subjects with depression and/or anxiety or other psychiatric conditions can be used as positive controls. In CWP, a prominent clinical feature is fatigue and in future studies this symptom needs to be considered. In addition, it is a cross sectional study that analyses the plasma proteome at one specific time. Another aspect worth considering when validating the results is the application of additional proteomic methods such as shot gun proteomics.

Conclusion
==========

This study suggests that different plasma protein patterns are associated with different pain intensities and psychological distress in CWP. Proteins belonging to the coagulation cascade and immunity processes showed strong association to each clinical outcome. Using the plasma proteome profile of CWP to study potential biomarker candidates provides a snapshot of ongoing systemic mechanisms in CWP. The effect seen systemically might be an effect of local peripheral changes in muscles and/or central changes such as central sensitization. This study suggests a numbers of potential candidates of plasma biomarkers in chronic pain that needs to be verified in different cohorts.
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